This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Gastroenterology  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Walter L. Peterson, MD; Deborah J. Cook, MD

JAMA. 1998;280:877-878.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

RECURRENT bleeding in patients hospitalized for bleeding peptic ulcer increases the need for surgery and the risk of death. The success of histamine₂ (H₂)–receptor antagonists in the treatment of symptomatic but uncomplicated peptic ulcer led to their widespread use in patients hospitalized for bleeding ulcers in the hope of preventing recurrent bleeding. In 1985, a landmark meta-analysis summarized the results of 27 randomized trials of cimetidine or ranitidine in 1673 patients with bleeding gastric or duodenal ulcer. The authors concluded that "treatment with H₂-receptor antagonists appears to be moderately promising" and called for large-scale studies to confirm their benefit.¹ Such a study was performed comparing intravenous famotidine with placebo in 1005 hospitalized patients whose ulcers showed signs of recent hemorrhage (SRH).² Rebleeding rates were similar in each group, occurring in 24% of patients treated with famotidine and 26% of those . . . [Full Text of this Article]

Results

Comment

Conclusion

Author Affiliations: From the Department of Medicine, University of Texas Southwestern Medical School at Dallas and Medical Service, Department of Veterans Affairs Medical Center, Dallas (Dr Peterson), and Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario (Dr Cook). Dr Cook is a Consulting Editor, JAMA. Dr Peterson is an ad hoc consultant to and has received honoraria and research funds from Astra Merck and Glaxo Wellcome. Dr Cook has received research supplies from Glaxo Wellcome.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?